<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02901587</url>
  </required_header>
  <id_info>
    <org_study_id>16323A</org_study_id>
    <nct_id>NCT02901587</nct_id>
  </id_info>
  <brief_title>Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder</brief_title>
  <official_title>Interventional, Randomised, Double-blind, Parallel-group, Active-control, Multiple-dose Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of Lu AF35700 on electrical activity
      in the heart as measured on an electrocardiogram (ECG) in patients with schizophrenia or
      schizoaffective disorder after 6 weeks of treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">April 18, 2018</completion_date>
  <primary_completion_date type="Actual">April 18, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from time-matched baseline on day 1, 21, and 42 in QTcF</measure>
    <time_frame>Before dose to 10 hours post dose</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Lu AF35700 (10 mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lu AF35700 10 mg/day for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AF35700 (30 mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lu AF35700 30 mg/day for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quetiapine (Seroquel XR® 800 mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine (Seroquel XR®) 800 mg/day for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF35700 (10 mg/day)</intervention_name>
    <description>tablets for oral administration once daily</description>
    <arm_group_label>Lu AF35700 (10 mg/day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AF35700 (30 mg/day)</intervention_name>
    <description>tablets for oral administration once daily</description>
    <arm_group_label>Lu AF35700 (30 mg/day)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine (Seroquel XR® 800 mg/day)</intervention_name>
    <description>tablets for oral administration once daily</description>
    <arm_group_label>Quetiapine (Seroquel XR® 800 mg/day)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is able by her/himself to provide informed consent to participate in the
             study

          -  The patient has a primary diagnosis of schizophrenia or schizoaffective disorder
             (DSM-5™ criteria)

          -  The patient has BMI ≤35 kg/m2

          -  The patient has a Clinical Global Impression - Severity of Illness (CGI-S) score ≤4
             (moderately ill)

          -  PANSS total score ≤ 80 and a score ≤4 (moderate) on the PANSS items, P7 (hostility)
             and G8 (uncooperativeness)

          -  The patient is willing to be hospitalized for up to 8 weeks

          -  The patient is generally healthy based on medical history, physical examination, vital
             signs, ECG, and laboratory tests.

          -  The patient agrees to protocol-defined use of effective contraception

        Exclusion Criteria:´

          -  The patient experienced acute exacerbation of psychosis requiring hospitalization
             within the last 3 months or required change in medication due to exacerbation of
             psychosis within the last 8 weeks

          -  The patient has met moderate or severe co-morbid Substance Abuse Disorder DSM-5™
             criteria in the last 3 months

          -  The patient is at significant risk of harming her/himself or others in the opinion of
             the investigator or according to Columbia Suicide Severity Rating Scale (C-SSRS)

          -  The patient has tested positive for human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg), or hepatitis C virus antibody (anti-HCV)

        Other protocol defined inclusion and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US1104</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2016</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

